BLOOD 2022: Zanubrutinib Shows Superiority Over Bendamustine + Rituximab in Treatment-Naive CLL/SLL
Zanubrutinib improved progression-free survival and was well tolerated
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.